Pharmacologic management of cancer pain.
Cancer pain has been referred to as a "thief of souls." When surveyed, patients with oncologic diseases indicated that of all possible outcomes, pain was that which they feared the most (Sutton, Porter, & Keefe, 2002). In a similar study, 60% of cancer patients surveyed claimed to have intolerable pain. This frequency rose to 90% in those with less than or equal to 1 month to live (Payne, 1997). Indeed, this sequela of malignancy may hinder quality of life to a great extent. All practitioners must understand pain management principles. This review discusses malignant pain pathophysiology and pharmacological treatment.
To effectively manage chronic malignant pain, the etiology of the pain must be ascertained. This does not refer to locating the presence of apparent tissue damage or disorders but the ability to decipher the etiology of transmission and maintenance. Painful stimuli, which are transmitted through intact afferent peripheral nerves as a result of tissue damage, are referred to, collectively, as nociception (Regan, Peng, & Chan, 1999). Nociceptive pain is generally described by the patient as constant, throbbing, crushing, aching, stabbing, and, uncommonly, burning. In addition, this type of pain typically manifests focally.
In contrast to nociceptive pain, neuropathic pain arises from direct damage, either traumatic or metabolic, to a primary afferent nerve (Woolf & Mannion, 1999). Because painful stimuli typically may not be required to elicit an action potential in these damaged neurons, neuropathic pain may be described as intermittent, stabbing, burning, "pins and needles," prickly, or a painful numbness. As compared to nociceptive pain, neuropathic pain is often described as shooting or radiating in quality. Because of the nature of neuropathic pain, it is often quite unpredictable and may prove difficult to treat with common modalities. Common causes of malignancy-related neuropathic pain may include chemotherapeutic agents, metabolic abnormalities, radiotherapy, and direct neoplastic nerve impingment. Neuropathic pain may prove difficult to manage (Besson, 1999; Fine & Ashburn, 1998).
While this provides a basic overview of the pathophysiologic mechanisms of pain, both nociceptive and neuropathic, cancer pain may present as a combination of these pain syndromes because of the enigma of processes and location of the neoplasm(s). Neoplasms may elicit painful responses from a host of factors including impingement, compression, or cytokine/peptide production. Any of these neurostimulatory processes may either lead to painful stimuli directly or decrease the threshold for which the nervous system responds to noxious stimuli (Levy, 1996).
The assessment of pain has been well studied over the past decade. Numerous assessment tools exist, ranging from one question to comprehensive interviews. Several of the more common, easy-to-use, validated assessment tools are provided in Figure 1. Because of the subjective nature of pain and the confounding factors that often exist in patients with malignancies, physiological monitoring endpoints (i.e., blood pressure, heart rate, and so on) should be reserved for patients who are unable to provide subjective characterization of their pain, such as during conscious sedation. Pain assessment should occur regularly, usually at change of shift or when other vital signs are obtained. Note that once a pain assessment tool is selected, that specific tool should be used throughout treatment to prevent interpatient variability (Chibnall & Tait, 2001; Cleeland & Ryan, 1994; Duggleby & Alden, 1998; Payne, 2000).
[FIGURE 1 OMITTED]
The World Health Organization (WHO) has published an "analgesic ladder" to aid practitioners in treating cancer-related pain states (Levy, 1996). This approach provides a framework from which to model practice. Step 1 of the WHO analgesic ladder recommends acetaminophen, nonsteroidal antiinflammatory drugs (NSAIDs), or adjuvants as first-line therapy for mild pain. Step 2 recommends "weak" opioids in combination with acetaminophen or NSAIDs, plus or minus adjuvants for the treatment of mild to moderate pain. Step 3 recommends "strong" opioids plus or minus acetaminophen, NSAIDs, or adjuvants.
Several barriers to successful pain management in the cancer patient exist by utilizing nonopioid analgesics. First, acetaminophen and most traditional NSAIDs are not without dose-limiting side effects and toxicities. Acetaminophen, in various conditions and doses, may contribute to hepatic failure (Schnitzer, 1998; Shimp, 1998; Tolman, 1998). Traditional NSAIDs possess dose-limiting toxicities, mainly, the risk for gastrointestinal ulceration and increased bleeding times, with other toxicities, such as prerenal azotemia, occurring at all dose ranges (Bjorkman, 1998; Cryer & Kimmey, 1998; Tolman). The newer cyclo-oxygenase II specific products (rofecoxib, celecoxib, and valdecoxib) exhibit a lower incidence of gastrointestinal ulceration, when utilized in the absence of aspirin, and platelet aggregation inhibition. However, these newer agents still pose a danger to patients with compromised renal function (Kaplan-Machlis & Klostermeyer, 1999). Dose titration to effect may be hindered by the addition of these agents in combination products. Aspirin, largely abandoned for its analgesic benefit, may still be found in opioid combination products and warrants similar cautions (hepatotoxicty, nephrotoxicity, and so on) as with those of acetaminophen and traditional NSAIDS (Bjorkman; Tolman).
Opioids possess very minimal unmanageable toxicities when utilized appropriately (Table 1). Common adverse drug reactions to opioids are constipation, nausea, somnolence, and pruritus. Less common side effects or adverse outcomes are confusion, respiratory depression, myoclonus, hypotension, and potential substance abuse (Bruera & Neumann, 1998; Mercadante, 1999; Walsh, 2000; Walsh, 1990). Opioids have no direct effect on renal or hepatic function; they do not affect coagulation. Particular attention should be paid to constipation because it is easily treated with stimulant laxatives and opioid antagonists and serious sequelae (impaction or narcotic gut syndrome) may be prevented. Nausea typically subsides within several days of initiation and may actually depend on the opioid used (i.e., morphine versus codeine) and its route of administration (i.e., oral versus intravenous). Somnolence, like nausea, is generally not a dose-limiting side effect and usually subsides within several days to 1 week of initiation. If somnolence is experienced, low-dose methylphenidate is often effective for treatment (Walsh, 2000; Walsh, Doona, Molnar, & Lipnickey, 2000; Walsh, 1990). Respiratory depression as a direct result of opioids is extremely rare (Vielvoye-Kerkmeer, Mattern, & Uitendaal, 2000; Walsh, 1990). Substance abuse disorder is commonly at the forefront of discussion and concern for patients. Studies have largely dispelled the belief that cancer pain patients may be at significant risk for substance abuse disorder (Medina & Diamond, 1977; Perry & Heidrich, 1982; Porter & Jick, 1980). In fact, less than 1% of patients started on opioids for pain management displayed any of the behaviors associated with substance abuse disorder. With this mind, it is important to consider "pseudoaddiction" in cancer pain management, in which aberrant drug-seeking behaviors are perceived not because of true substance abuse disorder, but from inadequate provision of analgesia by the healthcare professional (Kirsh, Whitcomb, Donaghy, & Passik, 2002). Physical dependence is a concern after 2 to 3 weeks of therapy. Withdrawal symptoms include agitation, diaphoresis, anxiety, confusion, and, in extreme cases, seizures. Discontinuation of an opioid should be done by titrating the dose down slowly, monitoring for these aforementioned symptoms frequently.
Instituting opioid therapy for cancer pain patients is relatively straightforward. Although several methods exist, the most commonly utilized strategy is presented (Coluzzi, 1998; McQuay, 1999; Mercadante, 1999). The opioid to be used should be determined first. The opioids of choice in cancer pain management are the pure [mu]-agonists. These include morphine, oxycodone, fentanyl, hydromorphone, methadone, morphine, and hydrocodone. Typically, all partial agonists/agonist-antagonists (buprenorphine, nalbuphine, pentazocine, butorphanol), as well as codeine, meperidine, and prophoxyphene, are avoided because of toxic metabolites or inability to titrate to increasing doses.
These medications, within their respective classes, are relatively homogenous with minor differences allowing the "finetuning" of analgesic therapy. The opioid of choice should be initiated first in its short-acting form. Beginning with the lowest available dose, the medication may be offered on an "as-needed" basis, with directions to take one or two doses every 2 hours. Although the duration of action for most opioids is 4 hours, peak analgesic effect is seen at approximately 1 and 1 1/2 to 2 hours. At this time the patient will know whether one dose is sufficient or whether a second dose is required. Under no circumstances should the interval between doses be limited to greater than 4 hours. To allow for steady-state accumulation of a drug, assessment of opioid utilization should be determined approximately 48 to 72 hours after initiation. By averaging the consumption of "as needed" doses in milligrams over a 24-hour period, total daily opioid need may be ascertained. Then the patient should be placed on scheduled, around-the-clock dosing, with the long-acting products providing more convenience for the patient and improved pain control. Conversion to a long-acting preparation of the same opioid as used in initial dosing is preferred to minimize the potential for uncontrolled pain or dose-related toxicities, which may be encountered when equianalgesic tables are used. Allowance for breakthrough pain episodes must be considered and a continued supply of the short-acting opioid made available (Levy, 1996; Portenoy, 1997; Walsh, 2000).
Breakthrough pain (BTP) is typically classified into three categories: incident, idiopathic, and end-of-dose failure (Portenoy & Hagen, 1990). Having the patient or caregiver administer a short-acting opioid dose to the patient 30 min. prior to the inciting stimulus (i.e., turning, ambulating, and the like) may usually prevent incident BTP. End-of-dose failure may be seen in as many as 30% of patients receiving long-acting opioids and is commonly experienced at consistent times of the day corresponding with the end of the analgesic window for the chosen opioid dosage form. Idiopathic BTP is by far the most common (Reddy & Nguyen, 2000). Immediaterelease opioid products should be used to manage this, reserving dose increases of long-acting opioids for instances in which four or more immediate-release opioid doses are being consumed per 24 hours. By attempting to treat baseline and breakthrough pain with long-acting products, the patient frequently experiences intolerable somnolence. When four or more immediate-release doses are needed per 24 hours, the long-acting product should be increased by the daily consumption of the immediate release product (i.e., four doses of 10 mg immediate release results in an increase in long-acting product by 40 mg). After the patient's pain scores are improving and no immediate release doses are needed, it is prudent to decrease the long-acting daily dose by 25% on weekly intervals as tolerated.
Opioids may be changed or rotated based upon equianalgesic potencies (Table 2). When changing opioids, it is prudent to decrease the total daily dose of the new medication by approximately 25% to avoid dose-dependent toxicities. This phenomenon is likely due to lack of cross-sensitivity among the various opioid subreceptors (Bruera et al., 1996; de Stoutz, Bruera, & Suarez-Almazor, 1995; Mercadante, 1999). Caution should be exercised when changing opioids based upon equianalgesic data widely published. Unfortunately, much of this data was acquired from single dose studies and has proven to be inaccurate in several instances (Bruera et al., 1996; Daeninck & Bruera, 1999; de Stoutz et al., 1995; Lawlor, Turner, Hanson, & Bruera, 1997; Mercadante, 1999). Most notable is methadone, which was originally thought to be equipotent to morphine. Recent reports suggest that this unique opioid may be as much as 10 times as potent as morphine, depending on previous patient opioid exposure (Bruera & Neumann, 1999; Mercadante et al., 1998; Mercadante, Casuccio, & Calderone, 1999). An outline of equianalgesic potencies between opioids and dosage forms is provided in Table 2.
While opioids are considered the mainstay of therapy for cancer pain management, some types of pain frequently experienced by oncology patients may not respond to opioids or other treatment modalities. Neuropathic pain has traditionally responded best to antidepressants and antiepileptic drugs. Oftentimes therapeutic doses for depression or seizures are unwarranted when neuropathic pain is being treated with these agents. These drugs should be initiated at low doses and titrated up to effect slowly, usually at weekly intervals. Amitriptyline, nortriptyline, desipramine, and gabapentin are currently considered first-line therapy for neuropathic pain with selection between these three agents based upon patient specific variables. Other promising agents for the treatment of neuropathic pain are clonidine, venlafaxine, fluvoxamine, mirtazipine, and tiagabine. In addition, mexiletine and transdermal lidocaine have shown benefit for neuropathic pain states as well (Lipman, 1998). Recent data suggest that opioids may be just as effective as antidepressants and antiepileptic drugs in certain types of neurogenically mediated pain syndromes (Raja et al., 2002).
Pain due to metastatic bone disease may respond to opioids, but generally the best effects are seen with NSAIDs, corticosteroids, and/or pamidronate. A radiopharmaceutical, strontium 89, may also be considered; however, the expense and delayed response typically preclude its use (McEwan, 1997). Calcitonin may also be of benefit for pain due to bone metastases; however, this effect is typically short lived (Payne, 1997).
Pain refractory to oral or parenteral analgesia may be responsive to alternative therapy. These methods should be considered on a patient-specific basis only. Cancer pain may be manageable with palliative doses of site-specific radiotherapy. Sources about radiation for pain management are available (Arcangeli et al., 1998; Gaze et al., 1997; Gressen, Werner-Wasik, Cohn, Topham, & Curran, 2000; Janjan, 1997). In addition, Interventional analgesia may be of use in the patient uncontrolled on standard therapy or unable to tolerate the less invasive alternatives. Interventional analgesia includes epidural, spinal, and intrathecal opioids, sometimes in combination with parenteral anesthetics (de Leon-Casasola, 2000; Miguel, 2000). Peripheral nerve blocks may be especially efficacious for short-term management of plexopathies involving the celiac, mesenteric, and subclavian plexus. Patients should be referred to trained pain specialists for these procedures. Trigger-point injections of corticosteroids, usually triamcinolone, may also be of benefit, but usually to a lesser degree.
Pain presents in various forms based upon site of stimulus, etiology, and mode of transmission. Choice of analgesic should be patient specific and tailored to provide the most convenience. Common side effects of these analgesics are easily treated and should be anticipated. Although this review is meant to provide a brief, working overview of malignancy-related pain, readers interested are urged to explore these areas discussed as well as numerous specific pain syndromes, human immunodeficiency virus related pain, as well as complex regional pain syndromes.
Table 1. Common Adverse Effects of Opioids and Their Management Adverse Effect Duration Constipation Indefinitely with ongoing opioid therapy Somnolence Usually subsiding within several days Myoclonus Rare in the absence of inappropriately high initiation or titration doses. Renal impairment may predispose those receiving morphine sulfate. Nausea Usually subsiding within several days postopioid initiation Pruritus May be seen with first several doses; result of mast cell destabilization. Respiratory Depression Extremely rare at recommended titration schedules Confusion May be seen at higher doses; usually subsides within days of initiation or dosage increase Adverse Effect Management Constipation Stimulant laxatives (senna, lactulose, sorbitol, bisacodyl) plus/minus softeners (docusate); naloxone may be of benefit orally in doses less than 18 milligrams per day. Somnolence Ongoing somnolence responds well to low doses of methylphenidate (5 mg am and noon). Myoclonus Benzodiazepines are the mainstay of treatment. Lorazepam and midazolam are by far the most studied. Phenobarbital is also of benefit. Nausea Primarily dopaminergic in etiology. Metoclopramide, prochlorperazine, promethazine, and haloperidol considered mainstays of therapy. May initiate prophylactically for 2-3 days when starting opioid. Pruritus Responds well to common antihistamines. Hydroxyzine or chlorpheniramine recommended as diphenhydramine may exacerbate somnolence. Respiratory Depression Naloxone should be administered. Confusion May respond to methylphenidate. Note: From "Cancer pain management, "by C.M. Herndon, 2001, Panhandle Health, 3. p. 30. Copyright 2001 by Panhandle Health. Reprinted with permission. Table 2. Classes and Conversion of Opioids Class Generic Name Conversion Ratio Agonists Morphine 1 * Hydromorphone 0.125-0.25 ([dagger]) Oxycodone 0.5 Methadone 0.1 ([double-dagger]) Hydrocodone 1-2.5 Meperidine 10 ([section]) Levorphanol 0.033 ([section]) Codeine 30 ([section]) Propoxyphene 50 ([section]) Fentanyl 0.01 (//) Sufentanyl 0.001 Alfentanyl 0.04 Remifentanyl N/A Oxymorphone 0.1 Agonist-Antagonists Nalbuphine 1 ([section]) Butorphanol 0.2 ([section]) Partial Agonists Dezocine 1 ([section]) Buprenorphine 0.04 ([section]) Antagonists Naloxone N/A (#) Naltrexone N/A Note: From "Cancer pain management. by C.M. Herndon, 2001. Panhandle Health, 3, p. 30. Copyright 2001 by Panhandle Health. Reprinted with permission. * Morphine considered standard for equianalgesic dosing. Conversion between oral and parenteral 3 to 1 (90 mg PO = 30 mg IV). ([dagger]) hydromorphone oral to parenteral conversion is 4 to 1 (40 mg PO = 10 mg IV). ([double-dagger]) Methadone conversion may range from 10% to 25% of morphine dose. Use should be limited to persons experienced with initiation and titration. ([section]) Use of these agents should generally be avoided in cancer-related pain. (//) Conversion based on parenteral dose of morphine. New data suggest this conversion should be utilized based on oral dose of morphine. Transmucosal fentanyl should not be dosed based upon total daily opioid consumption. Initiation should begin at lowest available dose and titrated up as needed. (#) Use caution when reversing meperidine with naloxone because of increased risk of seizure activity from unopposed normeperidine metabolite. Note: These equianalgesic ratios are approximate and critical clinical evaluation should follow the change of any medication. (Many of these figures are based upon poor or single-dose studies.)
Arcangeli, G., Giovinazzo, G., Saracino, B., D'Angelo, L., Giannarelli, D., & Micheli, A. (1998). Radiation therapy in the management of symptomatic bone metastases: The effect of total dose and histology on pain relief and response duration, International Journal of Radiation Oncology, Biology, Physics. 42(5), 1119-1126.
Besson, J.M. (1999). The neurobiology of pain. Lancet. 353(9164), 1610-1615.
Bjorkman, DJ. (1998). The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins. American Journal of Medicine. 105(1B), 8S-12S.
Bruera, E., & Neumann, C.M. (1998). Management of specific symptom complexes in patients receiving palliative care. Canadian Medical Association Journal, 158(13), 1717-1726.
Bruera, E.. & Neumann, C.M. (1999). Role of methadone in the management of pain in cancer patients. Oncology 13(9), 1275-1282; discussion 1285-1278, 1291.
Bruera, E., Pereira, J., Watanabe, S., Belzile, M., Kuehn, N., & Hanson, J. (1996). Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydro-morphone, and morphine. Cancer. 78(4), 852-857.
Caraceni, A., Cherny, N., Fainsinger, R., Kaasa. S.. Poulain, P., Radbruch, L., et al. (2002). Pain measurement tools and methods in clinical research in palliative care: Recommendations of an Expert Working Group of the European Association of Palliative Care. Journal of Pain and Symptom Management, 23(3), 239-255.
Chibnall, J.T., & Tait, R.C. (2001). Pain assessment in cognitively impaired and unimpaired older adults: A comparison of four scales. Pain. 92(1-2), 173-186.
Cleeland, C.S., & Ryan, K.M. (1994). Pain assessment: Global use of the Brief Pain Inventory. Annals of the Academy of Medicine, Singapore, 23(2), 129-138.
Coluzzi, P.H. (1998). Cancer pain management: Newer perspectives on opioids and episodic pain. American Journal of Hospice and Palliative Care. 15(1), 13-22.
Cryer, B., & Kimmey, M.B. (1998). Gastrointestinal side effects of nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 105(1B), 20S-30S.
Daeninck, P.J., & Bruera, E. (1999). Reduction in constipation and laxative requirements following opioid rotation to methadone: A report of four cases. Journal of Pain and Symptom Management, 18(4), 303-309.
de Leon-Casasola, O.A. (2000). Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. Cancer Control. 7(2), 142-148.
de Stoutz. N.D., Bruera, E., & Suarez-Almazor, M. (1995). Opioid rotation for toxicity reduction in terminal cancer patients. Journal of Pain and Symptom Management, 10(5), 378-384.
Duggleby, W., & Alden, C. (1998). Implementation and evaluation of a quality improvement process to improve pain management in a hospice setting. American Journal of Hospice and Palliative Care. 15(4), 209-216.
Fine, P.G., & Ashburn, M.A. (1998). Functional neuroanatomy and nociception. In M.A. Ashburn & P.G. Fine & T.H. Stanley (Eds.), The management of pain (pp. 1-16). Saint Louis: Kluwer Academic Publishers.
Gaze. M.N., Kelly, C.G., Kerr, G.R., Cull, A., Cowie, V.J., Gregor, A., et al. (1997). Pain relief and quality of life following radiotherapy for bone metastases: A randomised trial of two fractionation schedules. Radiotherapy and Oncology, 45(2), 109-116.
Gressen, E.L., Werner-Wasik, M., Cohn, J., Topham, A., & Curran, W.J., Jr. (2000). Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. American Journal of Clinical Oncology, 23(2), 160-163.
Janjan, N.A. (1997). Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals. Cancer. 80(8 Suppl), 1628-1645.
Kaplan-Machlis, B., & Klostermeyer, B.S. (1999). The cyclooxygenase2 inhibitors: Safety and effectiveness. Annals of Pharmacotherapy, 33(9), 979-988.
Kirsh. K.L., Whitcomb, L.A., Donaghy, K., & Passik, S.D. (2002). Abuse and addiction issues in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clinical Journal of Pain. 18(4 Suppl.), S52-60.
Lawlor, R. Turner. K., Hanson, J.. & Bruera, E. (1997). Dose ratio between morphine and hydromorphone in patients with cancer pain: A retrospective study. Pain, 72(1-2), 79-85.
Levy, M.H. (1996). Pharmacologic treatment of cancer pain. New England Journal of Medicine, 335(15). 1124-1132.
Lipman, A.G. (1998). Pharmacological approaches to pain management: Nontraditional analgesics and analgesic adjuvants. In M.A. Ashburn, P.G. Fine, & T.H. Stanley (Eds.), Pain Management and Anesthesiology (pp. 99-110). Saint Louis: Klewer Academic Publishers.
McEwan, A.J. (1997). Unsealed source therapy of painful bone metastases: An update. Seminals in Nuclear Medicine. 27(2), 165-182.
McQuay, H. (1999). Opioids in pain management. Lancet, 353(9171), 2229-2232.
Medina, J.L. & Diamond. S. (1977). Drug dependency in patients with chronic headaches. Headache, 17(1). 12-14.
Mercadante. S. (1999). Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer, 86(9), 1856-1866.
Mercadante, S., Casuccio, A., Agnello, A., Serretta, R., Calderone, L., & Barresi, L. (1998). Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. Journal of Clinical Oncology. 16(11), 3656-3661.
Mercadante, S., Casuccio, A., & Calderone, L. (1999). Rapid switching from morphine to methadone in cancer patients with poor response to morphine. Journal of Clinical Oncology, 17(10), 3307-3312.
Miguel, R. (2000). Interventional treatment of cancer pain: The fourth step in the World Health Organization analgesic ladder? Cancer Control, 7(2), 149-156.
Payne, R. (1997). Mechanisms and management of bone pain. Cancer, 80(8 Suppl), 1608-1613.
Payne, R. (2000). Chronic pain: Challenges in the assessment and management of cancer pain. Journal of Pain and Symptom Management. 19(1 Suppl). S12-15.
Perry, S., & Heidrich, G, (1982). Management of pain during debridement: A survey of U.S. burn units. Pain, 13(3), 267-280.
Portenoy, R.K., & Hagen, N.A. (1990). Breakthrough pain: Definition, prevalence and characteristics. Pain. 41(3), 273-281.
Porter J., & Jick, H. (1980), Addiction rare in patients treated with narcotics, New England Journal of Medicine, 302(2), 123.
Raja, S.N., Haythornthwaite, J.A., Pappagallo, M,, Clark, M.R., Travison, T.G., Sabeen, S., et al. (2002). Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology, 59(7), 1015-1021.
Reddy, S.K,, & Nguyen, P. (2000) Breakthrough pain in cancer patients: New therapeutic approaches to an old challenge. Current Revision of Pain, 4(3), 242-247.
Regan, J.M., Peng, P., & Chan. V.W. (1999). Neurophysiology of cancer pain: From the laboratory to the clinic. Current Revision of Pain, 3(3), 214-225.
Schnitzer, T.J. (1998). Non-NSAID pharmacologic treatment options for the management of chronic pain. American Journal of Medicine, 105(1B), 45S-52S.
Shimp, L.A. (1998). Safety issues in the pharmacologic management of chronic pain in the elderly. Pharmacotherapy. 18(6). 1313-1322.
Sutton, L., Porter. L., & Keefe, F. (2002). Cancer pain at the end of life: A biopsychosocial perspective. Pain, 99(1-2), 5.
Tolman, K. G. (1998). Hepatotoxicity of non-narcotic analgesics. American Journal of Medicine. 105(1B), 13S-19S.
Vielvoye-Kerkmeer, A.P., Mattern, C.. & Uitendaal, M.P. (2000). Transdermal fentanyl in opioid-naive cancer pain patients: An open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. Journal of Pain and Symptom Management. 19(3), 185-192.
Walsh, D, (2000). Pharmacological management of cancer pain. Seminals in Oncology. 27(1), 45-63.
Walsh, D.. Doona, M., Molnar, M., & Lipnickey, V. (2000). Symptom control in advanced cancer: Important drugs and routers of administration. Seminals in Oncology. 27(1), 69-83.
Walsh, T.D. (1990). Prevention of opioid side effects. Journal of Pain and Symptom Management. 5(6), 362-367.
Woolf, C.J., & Mannion, R.J. (1999). Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lanset, 353(9168), 1959-1964.
|Printer friendly Cite/link Email Feedback|
|Author:||Herndon, Christopher M.|
|Publication:||Journal of Neuroscience Nursing|
|Date:||Dec 1, 2003|
|Previous Article:||Cognitive symptoms and correlates of physical disability in individuals with multiple sclerosis.|
|Next Article:||The fundamentals of variant Creutzfeldt-Jakob disease.|